Evidence map›Paper›PMID 32586919›Full record

ArticleAnnals of the rheumatic diseases2022

Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani

Kristin M D'Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary S Wallace

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Kristin M D'SilvaRheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Naomi Serling-BoydRheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Rachel WallworkRheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Tiffany HsuDepartment of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Jeffrey A SparksDepartment of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0002-5556-4618
Zachary S WallaceRheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA zswallace@partners.org.ORCID http://orcid.org/0000-0003-4708-7038

Funding

Research Training in Rheumatology at Massachusetts General HospitalT32AR007258 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1986 to 2026
$6.9M
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated VasculitisK23AR073334 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2018 to 2022
$948k
NIAMS NIH HHS K23 AR073334NIAMS NIH HHS L30 AR070520NIAMS NIH HHS T32 AR007258
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antirheumatic AgentsBiological ProductsCOVID-19Janus Kinase InhibitorsRheumatic DiseasesHumansIncidenceAntirheumatic AgentsBiological ProductsJanus Kinase Inhibitorsantirheumatic agentsautoimmune diseasesepidemiology

Identifiers

PMID32586919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.